REPS2

Across TCGA pan-cancer cohorts, REPS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated REPS2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher REPS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated REPS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where REPS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.943	0.695	.001	28	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.876	.036	24	view →
CCRCC	DFS	Median	All	1.000	0.871	.004	19	view →
UCEC	OS	Tertile	All	1.000	0.853	.016	12	view →
LUAD	DFS	Tertile	III,IV	0.196	0.768	.002	11	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

REPS2–PDAC (OS)

Open the PDAC breakdown →